Trial result ·
Inflammatory cytokines, autoantibodies and salivary gland function in Sjögren's syndrome: Effects of T. wilfordii as Hook F medical wine and tripterygium glycosides tablets.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This randomised trial compared treatments for primary Sjögren's syndrome. One was a medical wine made from Tripterygium wilfordii Hook F (TWHF). The other was Tripterygium glycoside tablets. 90 patients were put in groups by chance. They took their treatment for 12 weeks. The main outcomes were saliva flow, a disease activity score, and antibody rates.
What they found
Both groups were similar at the start. After 12 weeks, the wine group improved more in saliva flow and disease activity score. Antibody-positive rates fell in both groups, more in the wine group. The gap between groups was not significant. Symptom scores and IgG levels fell in both groups, more in the wine group. No severe adverse events occurred.
What it means for patients
The authors conclude that the wine worked better than the tablets. This was for gland function, disease activity, and immune markers. They say safety was similar. They say it can serve as an alternative treatment for primary Sjögren's syndrome.
Why it is not certain yet
Only 90 patients took part, for 12 weeks. The antibody gap between groups was not significant. The comparison group took tablets, not a placebo. The abstract does not say if people knew which treatment they had.
Source
Inflammatory cytokines, autoantibodies and salivary gland function in Sjögren's syndrome: Effects of T. wilfordii as Hook F medical wine and tripterygium glycosides tablets.
PubMed · PMID 42021716We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Sjögren's disease publications